Global Anti-Venom Market Insights and Forecast to 2028

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Market Analysis and Insights: Global Anti-Venom Market
Due to the COVID-19 pandemic, the global Anti-Venom market size is estimated to be worth US$ 1002.9 million in 2022 and is forecast to a readjusted size of US$ 1283.7 million by 2028 with a CAGR of 4.2% during the review period. Fully considering the economic change by this health crisis, Polyvalent Anti-Venom accounting for % of the Anti-Venom global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Non-profit Institutions segment is altered to an % CAGR throughout this forecast period.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Global Anti-Venom Scope and Segment
Anti-Venom market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Anti-Venom market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Segment by Application
Non-profit Institutions
Hospitals and Clinic
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Frequently Asked Questions